1. Moretto J, Girard C, Demougeot C. The role of arginase in aging: a systematic review. Exp Gerontol. 2019; 116:54–73.
Article
2. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153:1194–217.
Article
3. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019; 15:565–81.
Article
4. Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012; 22:R741–52.
Article
5. Schosserer M, Grillari J, Wolfrum C, Scheideler M. Age-induced changes in white, brite, and brown adipose depots: a mini-review. Gerontology. 2018; 64:229–36.
Article
6. Barja G. Towards a unified mechanistic theory of aging. Exp Gerontol. 2019; 124:110627.
Article
7. Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014; 344:630–4.
Article
8. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011; 477:90–4.
Article
9. Laviano A. Young blood. N Engl J Med. 2014; 371:573–5.
Article
10. Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014; 20:659–63.
Article
11. Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013; 153:828–39.
Article
12. Rebo J, Mehdipour M, Gathwala R, Causey K, Liu Y, Conboy MJ, et al. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nat Commun. 2016; 7:13363.
Article
13. Kim BJ, Lee SH, Koh JM. Clinical insights into the kynurenine pathway in age-related diseases. Exp Gerontol. 2020; 130:110793.
Article
14. Choi KM. Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul). 2013; 28:86–9.
Article
15. Kim TN, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab. 2013; 20:1–10.
Article
16. Kim G, Kim JH. Impact of skeletal muscle mass on metabolic health. Endocrinol Metab (Seoul). 2020; 35:1–6.
Article
17. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48:16–31.
Article
18. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019; 393:2636–46.
Article
19. Dao T, Green AE, Kim YA, Bae SJ, Ha KT, Gariani K, et al. Sarcopenia and muscle aging: a brief overview. Endocrinol Metab (Seoul). 2020; 35:716–32.
Article
20. Lim HS, Park YH, Suh K, Yoo MH, Park HK, Kim HJ, et al. Association between sarcopenia, sarcopenic obesity, and chronic disease in Korean elderly. J Bone Metab. 2018; 25:187–93.
Article
21. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med. 1996; 183:2437–48.
Article
22. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996; 2:449–56.
Article
23. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med. 1994; 179:881–7.
Article
24. Kindstedt E, Holm CK, Sulniute R, Martinez-Carrasco I, Lundmark R, Lundberg P. CCL11, a novel mediator of inflammatory bone resorption. Sci Rep. 2017; 7:5334.
Article
25. Lee JY, Park SJ, Kim DA, Lee SH, Koh JM, Kim BJ. Muscle-derived lumican stimulates bone formation via integrin α2β1 and the downstream ERK signal. Front Cell Dev Biol. 2020; 8:565826.
Article
26. Kim BJ, Lee YS, Lee SY, Baek WY, Choi YJ, Moon SA, et al. Osteoclast-secreted SLIT3 coordinates bone resorption and formation. J Clin Invest. 2018; 128:1429–41.
Article
27. Park SJ, Lee JY, Lee SH, Koh JM, Kim BJ. SLIT2 inhibits osteoclastogenesis and bone resorption by suppression of Cdc42 activity. Biochem Biophys Res Commun. 2019; 514:868–74.
Article
28. Jang IY, Lee S, Kim JH, Lee E, Lee JY, Park SJ, et al. Lack of association between circulating apelin level and frailty-related functional parameters in older adults: a cross-sectional study. BMC Geriatr. 2020; 20:420.
Article
29. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011; 40:423–9.
Article
30. Peel NM, Kuys SS, Klein K. Gait speed as a measure in geriatric assessment in clinical settings: a systematic review. J Gerontol A Biol Sci Med Sci. 2013; 68:39–46.
Article
31. Jung HW, Roh H, Cho Y, Jeong J, Shin YS, Lim JY, et al. Validation of a multi-sensor-based kiosk for short physical performance battery. J Am Geriatr Soc. 2019; 67:2605–9.
Article
32. Oh JH, Song S, Rhee H, Lee SH, Kim DY, Choe JC, et al. Normal reference plots for the bioelectrical impedance vector in healthy Korean adults. J Korean Med Sci. 2019; 34:e198.
Article
33. Jang IY, Jung HW, Lee CK, Yu SS, Lee YS, Lee E. Comparisons of predictive values of sarcopenia with different muscle mass indices in Korean rural older adults: a longitudinal analysis of the Aging Study of PyeongChang Rural Area. Clin Interv Aging. 2018; 13:91–9.
Article
34. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020; 21:300–7.
Article
35. Kitaura M, Nakajima T, Imai T, Harada S, Combadiere C, Tiffany HL, et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem. 1996; 271:7725–30.
Article
36. Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood. 2001; 97:1920–4.
Article
37. Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. Arch Neurol. 2009; 66:1339–44.
Article
38. Gray SL, Anderson ML, Hubbard RA, LaCroix A, Crane PK, McCormick W, et al. Frailty and incident dementia. J Gerontol A Biol Sci Med Sci. 2013; 68:1083–90.
Article
39. Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone density and brain atrophy in early Alzheimer’s disease. J Alzheimers Dis. 2009; 18:777–85.
Article
40. Ye J, Kohli LL, Stone MJ. Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3. J Biol Chem. 2000; 275:27250–7.
Article
41. Alblowi J, Tian C, Siqueira MF, Kayal RA, McKenzie E, Behl Y, et al. Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. Bone. 2013; 53:294–300.
Article